WEST PALM BEACH, Fla., Sept. 2, 2020 /PRNewswire/ -- Diagnostic Centers of America (DCA) and Boca Radiology Group has partnered with ScreenPoint Medical, Inc., to improve early detection and treatment using Transpara®, an AI solution that uses deep learning algorithms.
ScreenPoint Medical, Inc. has developed Transpara®, the world's first dedicated breast AI decision support solution for 2D and 3D mammography. As part of their mission to provide patients with the highest quality imaging available through innovative technology, DCA has implemented Transpara® across their enterprise.
"When it comes to breast imaging, we are focused on helping to improve breast cancer survival rates by detecting cancers earlier. Our specialized breast radiologists are current leaders in this field. Transpara® will complement what they already do so well and keep us at the forefront of medical technology," says Steven Shullman, CEO of Diagnostic Centers of America.
Numed, a well established company in business since 1975 provides a wide range of service options including time & material service, PM only contracts, full service contracts, labor only contracts & system relocation. Call 800 96 Numed for more info.
ScreenPoint has assembled a world-class team of researchers and engineers with extensive experience in breast imaging, machine learning, algorithm development, and clinical research. The team is highly motivated to develop technology that can make a difference in the early detection of breast cancer. Close collaboration with the radiologists from BRG and others around the world ensures superior performance of Transpara's detection algorithms.
Boca Radiology Group's Dr. Matthew Saady says, "My colleagues and I interpret tens of thousands of mammograms every year. We are committed to accuracy, consistency and reducing unnecessary recalls, which is a common cause of anxiety for women undergoing mammography. We recognize that each of our patients has a unique short-term and long-term risk of developing breast cancer. After reviewing the evidence about available AI solutions, we determined that Transpara® can best help us to identify those patients with short-term risk. Coupling that with factors such as breast density and family history, we can make the best decision about each patient screening that we review. Transpara® meets our clinical needs and fits seamlessly into the workflow of our busy screening practice."
Steven Shullman adds, "DCA regularly purchases what we consider to be best-in-class technology. That said, we work with a variety of modality and IT vendors. It was important that we select an AI partner who is committed to interfacing with multiple vendors to deliver a fast and efficient workflow for our physicians. ScreenPoint is working closely with us to do just that."